Carvolix (formerly Caranx Medical)
French cardiac medtech company (formerly Caranx Medical), developer of the FDA-cleared TAVIPILOT AI software for transcatheter heart valve implantation.
Caranx Medical was founded in 2019 and is based in Nice, France. The company developed the AiiR platform integrating AI, image-guided intervention, and robotics for transcatheter aortic valve implantation (TAVI). Its flagship product, TAVIPILOT Soft, received FDA clearance in July 2025 as the world's first AI software authorized for real-time intraoperative guidance of transcatheter heart valve implantation.
First clinical use of TAVIPILOT Soft was completed in October 2025 at Clinique Pasteur in Toulouse. In January 2026, Caranx Medical was acquired by Affluent Medical alongside Artedrone, with the combined entity rebranding as Carvolix — a French clinical-stage company specializing in AI-driven mini-robots and biomimetic implants for interventional cardiology. The company website caranx-medical.com now redirects to carvolix.eu.
Co-founders include Dr. Eric Sejor (CMO) and Pierre Berthet-Rayne (CTO).
Primary type & automation activities this supplier delivers:
TAVIPILOT Soft
FDA-cleared AI software for real-time intraoperative guidance of transcatheter aortic valve implantation (TAVI).
More related news
- 1
- 2
- 3
- 4
- 5
- 6
- 7
-
8
How Yuanhua Robotics’ 5,000 Surgeries Are Redefining Trust in China’s AI Surgical Robots RobotToday · Oct 16, 2025
- 9
- 10
-
11
RobotToday Weekly October 12 – 16, 2026 RobotToday · Oct 17, 2026
- 12
- 13
-
14
Suzy Teele’s Mission at ARM Institute RobotToday · Oct 13, 2026
- 15
- 16
Contact Carvolix (formerly Caranx Medical)
WEBSITE
https://carvolix.euPHONE
+33(0)982248561HEADQUARTERS
France
Company Facts
Founded
2019
Primary Role
Manufacturer
Company Size
-
Primary Region
Europe
Annual Sales
-
Funding Stage
-
Funding Total
-
Certifications & Memberships
